Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $23,480.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 2,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $11.74, for a total value of $23,480.00. Following the transaction, the president now directly owns 2,835,260 shares in the company, valued at approximately $33,285,952.40. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total transaction of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total transaction of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
• On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.
• On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
• On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.

Gyre Therapeutics Price Performance

GYRE stock traded up $0.29 during trading on Thursday, reaching $11.96. 75,657 shares of the company traded hands, compared to its average volume of 73,808. The business has a 50 day simple moving average of $11.24 and a 200 day simple moving average of $12.32. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $19.96.

Wall Street Analysts Forecast Growth

Separately, Noble Financial assumed coverage on Gyre Therapeutics in a report on Tuesday. They set an "outperform" rating for the company.

Remove Ads

Institutional Trading of Gyre Therapeutics

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Gyre Therapeutics by 0.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 114,566 shares of the company's stock valued at $1,386,000 after buying an additional 918 shares during the last quarter. State Street Corp boosted its holdings in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after acquiring an additional 8,412 shares in the last quarter. Northern Trust Corp grew its stake in shares of Gyre Therapeutics by 9.1% during the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after acquiring an additional 8,624 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Gyre Therapeutics during the fourth quarter valued at about $1,225,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.